Nature Medicine corrects figure labels in cevostamab multiple myeloma phase 1 trial paper
Start here
Nature Medicine has issued an Author Correction to a phase 1 trial of cevostamab, an FcRH5×CD3 bispecific antibody, in relapsed or refractory multiple myeloma. The correction concerns Extended Data Fig. 3b: the left x-axis labels of both panels have been changed from "No 1q gain or amp" to "1q normal". The HTML and PDF versions of the article have been updated to reflect the change. No other alterations to the trial data or conclusions were reported in the correction notice.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- NatureAuthor Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Nature Medicine has published an Author Correction to the phase 1 trial of cevostamab, an FcRH5×CD3 bispecific antibody, in relapsed or refractory multiple myeloma. The left x-axis labels of both panels in Extended Data Fig. 3b are changed from "No 1q gain or amp" to "1q normal". The HTML and PDF versions have been updated.
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 20 08:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.